account_id none on file
legal_name Kiniksa Pharmaceuticals International, plc
ticker KNSA
cik 1730430
domain kiniksa.com
linkedin_company_url https://www.linkedin.com/company/kiniksa-pharmaceuticals/
entry_point_account_id none on file
name Kiniksa Pharmaceuticals International plc
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 3 executives 2 family 0
why_nownone on file
callsnone on file
filings
The increase of $17.0 million was primarily due to an increase of $9.6 million in personnel-related costs largely attributable to an increase in headcount and an increase in sales and marketing expenses of $4.8 million largely attributable to increased promotional activities, including our
filing / Jul 28, 2026 / receipt
The increase of $34.6 million was primarily due to an increase of $20.4 million in personnel-related costs largely attributable to an increase in headcount and an increase in sales and marketing costs of $10.0 million largely attributable to promotional activities, including our direct-to-consumer advertising campaign.
filing / Jul 28, 2026 / receipt
The increase of $17.6 million was primarily due to an increase of $10.8 million in personnel-related costs largely attributable to an increase in headcount and an increase in sales and marketing expenses of $5.2 million largely attributable to increased promotional activities and the timing of free goods designation.
filing / Apr 28, 2026 / receipt
executives
| Eben Tessari | Chief Strategy Officer | - | receipt |
| Ross Moat | Chief Operating Officer | - | receipt |
familynone on file
upcoming
| 2026-10-27 | earnings call | scheduled | ir |
changes
| 2026-01-14 | Chief Operating Officer, appointed | sec_8k |
| 2026-01-14 | Chief Strategy Officer, appointed | sec_8k |
mcp_package_hint
slug kiniksa-pharmaceuticals-international-plc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$